Halozyme Therapeutics Inc. (Nasdaq: HALO) positive topline results from a Phase 2 study of PEGPH20 in combination with ABRAXANE and gemcitabine to treat stage IV pancreas cancer patients. Shares of the biotechnology firm climbed $1.92 to close at $12.61.
Halozyme Therapeutics reports upbeat study results
January 05, 2017 at 18:43 PM EST
